Nifty
:
24154.90
Sensex
:
77235.46
-132.75 (-0.55%)
-492.70 (-0.63%)
Nifty
Sensex
:
:
24154.90
77235.46
-132.75 (-0.55%)
-492.70 (-0.63%)

Neuland Laboratories Ltd.

Pharmaceuticals & Drugs - API

Rating :
80/99

BSE: 524558 | NSE: NEULANDLAB

NSE BSE
23370.00
18-Aug-2026
  • Open
  • High
  • Low
  • Previous Close
  •  23670
  •  23881
  •  23264
  •  23661.00
  • Volume
  • Traded Value (lacs)
  • 52 Week High
  • 52 Week Low
  •  55362
  •  1300476503
  •  23881
  •  11500

Stock Summary

  • Market Cap(Crs)
  • Stock P:E
  • Face Value
  • 29,919.11
  • 60.11
  • 10
  • Enterprise Value(Crs)
  • Dividend Yield
  • Price:Book Value
  • 29,760.76
  • 0.15%
  • 14.80

Shareholding Pattern

  • Promoter
  • Corporate
  • Public
  • 32.62%
  • 4.67%
  • 22.88%
  • FII
  • DII
  • Others
  • 21.08%
  • 13.94%
  • 4.81%

Chart

Price | P:E | P:BV | EV:EBITDA | MCap:Sales | EPS

Revenue CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 13.33
  • 16.29
  • 9.08

EBITDA CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 18.37
  • 32.14
  • 4.43

PAT CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 22.75
  • 41.65
  • 6.65

P:E (Median)

  • 8 Years
  • 5 Years
  • 3 Years
  • 37.10
  • 29.14
  • 57.46

P:BV (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 5.16
  • 7.04
  • 10.07

EV:EBITDA (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 23.07
  • 27.97
  • 37.83

Earnings Forecasts:

(Updated: 15-08-2026)
Description
2026
2027
2028
2029
Adj EPS
59
23
50.21
199.77
P/E Ratio
396.10
1016.09
465.45
116.98
Revenue
58.09
42.13
31.84
1761.93
EBITDA
2322.3
2754.95
3608.3
422.4
Net Income
645.33
866
1118.6
257.27
ROA
420.93
580.57
765.1
-
P/B Ratio
-10340.71
-4015.46
-
17.01
ROE
10.76
8.65
-
15.63
FCFF
20.3
22.77
-
38.11
FCFF Yield
371.69
330.08
444.28
0.16
Net Debt
1.53
1.36
1.83
0.23
BVPS
-2.26
-5.82
-
1374.23

Quarterly Results

Consolidated Figures in Rs. Crores /

Standalone
Description
Jun 26
Jun 25
Var%
Mar 26
Mar 25
Var%
Dec 25
Dec 24
Var%
Sep 25
Sep 24
Var%
Net Sales
641.58
292.75
119.16%
776.25
328.36
136.40%
439.71
398.03
10.47%
514.27
310.84
65.45%
Expenses
418.69
258.26
62.12%
468.92
277.29
69.11%
362.58
311.43
16.42%
358.73
248.62
44.29%
EBITDA
222.89
34.49
546.25%
307.33
51.07
501.78%
77.13
86.60
-10.94%
155.55
62.23
149.96%
EBIDTM
34.74%
11.78%
39.59%
15.55%
17.54%
21.76%
30.25%
20.02%
Other Income
8.49
7.86
8.02%
12.46
7.46
67.02%
8.05
3.91
105.88%
1.80
4.33
-58.43%
Interest
6.97
4.59
51.85%
7.21
2.35
206.81%
6.79
2.22
205.86%
5.37
1.06
406.60%
Depreciation
26.56
20.19
31.55%
25.09
16.89
48.55%
23.92
16.30
46.75%
22.54
16.07
40.26%
PBT
197.85
17.57
1,026.07%
287.50
39.30
631.55%
54.48
127.77
-57.36%
129.44
49.42
161.92%
Tax
50.17
3.67
1,267.03%
74.82
11.49
551.17%
13.90
26.18
-46.91%
32.58
16.58
96.50%
PAT
147.67
13.90
962.37%
212.67
27.80
665.00%
40.57
101.59
-60.06%
96.85
32.84
194.91%
PATM
23.02%
4.75%
27.40%
8.47%
9.23%
25.52%
18.83%
10.57%
EPS
114.48
10.78
961.97%
164.86
21.55
665.01%
31.45
78.75
-60.06%
75.07
25.46
194.85%

Annual Results

Consolidated Figures in Rs. Crores /

Standalone
Description
TTM
Mar 26
Mar 25
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Net Sales
2,371.81
2,022.99
1,476.84
1,558.58
1,191.20
951.08
936.91
762.71
666.83
527.41
578.89
Net Sales Growth
78.33%
36.98%
-5.24%
30.84%
25.25%
1.51%
22.84%
14.38%
26.43%
-8.89%
 
Cost Of Goods Sold
862.98
755.50
587.64
577.29
478.23
422.14
438.42
380.20
366.24
238.37
262.90
Gross Profit
1,508.83
1,267.48
889.20
981.30
712.97
528.94
498.50
382.51
300.59
289.04
315.99
GP Margin
63.62%
62.65%
60.21%
62.96%
59.85%
55.61%
53.21%
50.15%
45.08%
54.80%
54.59%
Total Expenditure
1,608.92
1,448.49
1,153.58
1,095.99
919.36
808.46
790.09
660.82
608.46
476.98
472.55
Power & Fuel Cost
-
58.14
50.56
48.72
48.62
42.21
39.21
32.75
26.81
25.95
25.78
% Of Sales
-
2.87%
3.42%
3.13%
4.08%
4.44%
4.19%
4.29%
4.02%
4.92%
4.45%
Employee Cost
-
341.14
272.00
257.06
201.79
182.47
149.74
123.56
110.46
102.99
92.74
% Of Sales
-
16.86%
18.42%
16.49%
16.94%
19.19%
15.98%
16.20%
16.56%
19.53%
16.02%
Manufacturing Exp.
-
133.47
112.31
107.79
86.94
89.16
77.10
64.84
50.10
55.54
44.90
% Of Sales
-
6.60%
7.60%
6.92%
7.30%
9.37%
8.23%
8.50%
7.51%
10.53%
7.76%
General & Admin Exp.
-
109.39
84.81
60.91
51.22
35.80
38.93
27.75
27.49
33.32
28.30
% Of Sales
-
5.41%
5.74%
3.91%
4.30%
3.76%
4.16%
3.64%
4.12%
6.32%
4.89%
Selling & Distn. Exp.
-
30.90
23.83
33.94
29.58
27.40
34.63
18.30
18.28
14.04
11.16
% Of Sales
-
1.53%
1.61%
2.18%
2.48%
2.88%
3.70%
2.40%
2.74%
2.66%
1.93%
Miscellaneous Exp.
-
19.94
22.42
10.29
22.99
9.28
12.08
13.42
9.08
6.77
11.16
% Of Sales
-
0.99%
1.52%
0.66%
1.93%
0.98%
1.29%
1.76%
1.36%
1.28%
1.17%
EBITDA
762.90
574.50
323.26
462.59
271.84
142.62
146.82
101.89
58.37
50.43
106.34
EBITDA Margin
32.17%
28.40%
21.89%
29.68%
22.82%
15.00%
15.67%
13.36%
8.75%
9.56%
18.37%
Other Income
30.80
30.17
20.51
12.54
9.75
2.08
16.10
3.89
3.49
4.53
1.17
Interest
26.34
23.95
8.30
14.00
13.07
13.50
17.90
21.57
15.66
18.93
21.09
Depreciation
98.11
91.74
65.55
59.70
52.78
49.04
39.68
31.28
25.86
22.10
19.23
PBT
669.27
488.98
269.93
401.44
215.75
82.16
105.33
52.92
20.34
13.93
67.19
Tax
171.47
124.98
86.22
101.36
52.23
18.34
24.70
36.71
3.90
1.87
20.32
Tax Rate
25.62%
25.56%
24.90%
25.25%
24.21%
22.32%
23.45%
69.37%
19.17%
13.42%
30.24%
PAT
497.76
364.00
260.11
300.08
163.52
63.82
80.63
16.21
16.44
12.06
46.86
PAT before Minority Interest
497.76
364.00
260.11
300.08
163.52
63.82
80.63
16.21
16.44
12.06
46.86
Minority Interest
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
PAT Margin
20.99%
17.99%
17.61%
19.25%
13.73%
6.71%
8.61%
2.13%
2.47%
2.29%
8.09%
PAT Growth
182.61%
39.94%
-13.32%
83.51%
156.22%
-20.85%
397.41%
-1.40%
36.32%
-74.26%
 
EPS
388.88
284.38
203.21
234.44
127.75
49.86
62.99
12.66
12.84
9.42
36.61

Results Balance Sheet

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 26
Mar 25
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Shareholder's Funds
1,874.47
1,524.81
1,282.70
994.10
840.50
786.46
709.96
699.31
558.04
545.62
Share Capital
12.90
12.90
12.90
12.90
12.90
12.90
12.90
12.90
8.95
8.95
Total Reserves
1,861.57
1,511.91
1,269.80
981.20
827.60
773.56
697.06
686.41
238.24
225.81
Non-Current Liabilities
345.47
189.39
122.17
146.71
179.83
169.82
163.39
104.06
146.43
54.37
Secured Loans
160.95
90.73
44.92
74.25
104.25
88.13
77.37
60.72
103.49
29.81
Unsecured Loans
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Long Term Provisions
15.86
7.22
7.61
10.29
11.91
9.44
12.49
11.91
9.87
9.28
Current Liabilities
710.20
465.69
427.68
438.96
363.16
368.51
357.63
326.98
366.93
285.60
Trade Payables
269.14
252.20
191.96
171.01
117.38
152.13
115.56
119.68
124.29
85.92
Other Current Liabilities
420.59
211.30
234.01
244.87
152.35
158.75
71.63
57.45
41.83
47.18
Short Term Borrowings
0.00
0.00
0.00
11.16
92.21
56.98
168.17
149.06
199.20
151.08
Short Term Provisions
20.46
2.19
1.72
11.93
1.21
0.64
2.27
0.80
1.59
1.41
Total Liabilities
2,930.14
2,179.89
1,832.55
1,579.77
1,383.49
1,324.79
1,230.98
1,130.35
1,071.40
885.59
Net Block
1,176.93
954.92
804.64
738.19
747.70
696.94
622.76
511.69
445.01
435.74
Gross Block
1,531.51
1,233.31
1,069.76
950.36
913.27
826.48
714.33
575.44
483.45
454.74
Accumulated Depreciation
354.58
278.40
265.12
212.17
165.57
129.54
91.57
63.75
38.44
19.00
Non Current Assets
1,447.01
1,040.38
911.48
818.87
802.70
775.20
715.79
676.88
624.20
510.54
Capital Work in Progress
210.58
47.66
45.89
40.57
20.46
17.25
23.75
104.47
126.09
19.60
Non Current Investment
1.98
1.53
1.28
0.52
0.50
0.44
0.36
0.40
0.40
0.38
Long Term Loans & Adv.
57.36
36.04
40.47
20.24
14.38
41.67
35.81
30.51
22.66
24.79
Other Non Current Assets
0.16
0.23
0.17
0.00
0.00
0.00
3.30
0.00
0.22
0.22
Current Assets
1,483.13
1,139.50
921.08
760.89
580.79
549.59
515.19
453.47
447.19
375.04
Current Investments
0.00
107.68
0.00
0.00
3.38
6.46
7.50
7.50
7.50
7.50
Inventories
510.29
385.76
350.42
279.23
265.21
247.61
219.55
192.65
175.09
135.11
Sundry Debtors
541.35
315.72
373.53
361.77
234.33
217.73
189.89
164.02
193.92
181.11
Cash & Bank
354.96
258.82
116.80
59.10
20.36
19.40
46.98
37.84
17.26
12.49
Other Current Assets
76.53
19.70
18.30
13.70
57.52
58.39
51.27
51.45
53.43
38.83
Short Term Loans & Adv.
51.98
51.82
62.03
47.09
46.00
49.55
35.92
33.59
38.46
25.41
Net Current Assets
772.93
673.81
493.40
321.94
217.64
181.08
157.55
126.49
80.27
89.45
Total Assets
2,930.14
2,179.88
1,832.56
1,579.76
1,383.49
1,324.79
1,230.98
1,130.35
1,071.39
885.58

Cash Flow

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 26
Mar 25
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Cash From Operating Activity
346.68
317.40
261.18
237.21
60.39
189.36
57.34
69.91
11.27
38.68
PBT
488.98
346.33
401.44
215.75
82.16
105.33
52.92
20.34
13.93
67.19
Adjustment
102.65
-11.98
62.08
77.93
66.30
40.08
58.28
39.11
40.43
43.96
Changes in Working Capital
-141.42
57.78
-90.73
-12.83
-67.58
49.22
-49.17
15.47
-40.02
-55.94
Cash after chg. in Working capital
450.21
392.13
372.78
280.84
80.88
194.63
62.03
74.91
14.35
55.20
Interest Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Tax Paid
-103.53
-74.73
-111.60
-43.63
-20.49
-5.27
-4.68
-5.01
-3.08
-16.52
Other Direct Exp. Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Extra & Other Items
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Cash From Investing Activity
-423.73
-298.16
-149.69
-61.50
-95.52
-84.42
-48.68
-77.23
-116.29
-42.11
Net Fixed Assets
-456.21
-170.21
-121.81
-60.11
-90.00
-105.64
-58.17
-70.35
-135.20
-142.08
Net Investments
107.23
-107.93
-0.76
3.36
3.02
0.96
0.04
0.00
-0.02
-0.49
Others
-74.75
-20.02
-27.12
-4.75
-8.54
20.26
9.45
-6.88
18.93
100.46
Cash from Financing Activity
20.98
24.96
-69.28
-135.80
37.72
-113.66
-5.48
11.98
104.85
-0.09
Net Cash Inflow / Outflow
-56.08
44.21
42.21
39.92
2.59
-8.72
3.18
4.66
-0.17
-3.51
Opening Cash & Equivalents
131.93
87.58
45.42
5.09
2.44
11.20
7.94
3.29
3.44
6.97
Closing Cash & Equivalent
76.67
131.93
87.58
45.42
5.09
2.44
11.20
7.94
3.29
3.44

Financial Ratios

Consolidated /

Standalone
Description
Mar 26
Mar 25
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Book Value (Rs.)
1460.31
1187.77
999.07
774.12
654.40
612.28
552.65
544.35
277.21
263.23
ROA
14.25%
12.97%
17.59%
11.04%
4.71%
6.31%
1.37%
1.49%
1.23%
6.65%
ROE
21.43%
18.54%
26.38%
17.84%
7.85%
10.79%
2.30%
3.48%
5.02%
22.34%
ROCE
27.50%
23.45%
33.51%
20.94%
9.44%
12.81%
7.85%
3.99%
4.07%
15.98%
Fixed Asset Turnover
1.46
1.28
1.54
1.28
1.09
1.22
1.18
1.26
1.13
1.57
Receivable days
77.32
85.17
86.10
91.33
86.74
79.40
84.68
97.96
129.34
93.22
Inventory Days
80.83
90.97
73.73
83.41
98.40
91.00
98.63
100.64
106.98
81.29
Payable days
125.94
137.94
114.75
110.05
116.52
111.44
65.43
75.72
82.06
67.03
Cash Conversion Cycle
32.22
38.21
45.08
64.68
68.63
58.96
117.88
122.89
154.27
107.48
Total Debt/Equity
0.10
0.09
0.06
0.12
0.28
0.22
0.37
0.33
1.30
0.82
Interest Cover
21.42
42.74
29.68
17.51
7.09
6.89
3.45
2.30
1.74
4.19

Annual Reports:

FY 2026
FY 2025
FY 2024
FY 2023
FY 2022
FY 2021
FY 2020
FY 2019
FY 2018
FY 2017

News Update:


  • USFDA inspects Neuland Laboratories’ manufacturing facility in Telangana
    17th Aug 2026, 11:57 AM

    At the conclusion of the inspection, the USFDA issued a Form 483 with one observation.

    Read More
  • Neuland Laboratories - Quarterly Results
    6th Aug 2026, 00:00 AM

    Read More

Source: www.accordfintech.com | DISCLAIMER: Information is provided " as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.